FibroGen, Inc. Announces Pricing Of Its IPO

SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs, today announces the pricing of its initial public offering of 8,100,000 shares of its common stock at a public offering price of $18.00 per share, before underwriting discounts and commissions. All of the shares are being offered by FibroGen. FibroGen completed a 1-for-2.5 reverse stock split effective as of November 10, 2014. The shares are expected to begin trading on The NASDAQ Global Select Market under the ticker symbol "FGEN" on November 14, 2014. In addition, FibroGen has granted the underwriters a 30-day option to purchase up to an additional 1,215,000 shares of common stock from FibroGen at the initial public offering price. The offering is expected to close on November 19, 2014, subject to customary closing conditions.

Help employers find you! Check out all the jobs and post your resume.